Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and def ines basal-like breast tumors

被引:180
作者
Gauthier, Mona L.
Berman, Hal K.
Miller, Caroline
Kozakeiwicz, Krystyna
Chew, Karen
Moore, Dan
Rabban, Joseph
Chen, Yunn Yi
Kerlikowske, Karla
Tlsty, Thea D. [1 ]
机构
[1] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[4] Calif Pacific Med Ctr, San Francisco, CA 94107 USA
[5] Univ Calif San Francisco, Gen Internal Med Sect, Dept Vet Affairs, San Francisco, CA 94121 USA
关键词
D O I
10.1016/j.ccr.2007.10.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Approximately 15%-30% of women diagnosed with ductal carcinoma in situ (DCIS) develop a subsequent tumor event within 10 years after surgical lumpectomy. To date, little is known about the molecular pathways that confer this differential risk for developing subsequent disease. In this study, we demonstrate that expression of biomarkers indicative of an abrogated response to cellular stress predicts DCIS with worse outcome and is a defining characteristic of basal-like invasive tumors. Mechanistic studies identify the Rb pathway as a key regulator of this response. Conversely, biomarkers indicative of an intact response to cellular stress are strongly associated with a disease-free prognosis. Assessment of these biomarkers in DCIS begins to allow prediction of tumor formation years before it actually occurs.
引用
收藏
页码:479 / 491
页数:13
相关论文
共 71 条
[1]  
Adeyinka A, 2002, CLIN CANCER RES, V8, P3788
[2]  
Allred DC, 1998, MODERN PATHOL, V11, P155
[3]   Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence [J].
Barnes, N ;
Haywood, P ;
Flint, P ;
Knox, WF ;
Bundred, NJ .
BRITISH JOURNAL OF CANCER, 2006, 94 (02) :253-258
[4]   DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis [J].
Bartkova, J ;
Horejsi, Z ;
Koed, K ;
Krämer, A ;
Tort, F ;
Zieger, K ;
Guldberg, P ;
Sehested, M ;
Nesland, JM ;
Lukas, C ;
Orntoft, T ;
Lukas, J ;
Bartek, J .
NATURE, 2005, 434 (7035) :864-870
[5]  
BATES S, 1994, ONCOGENE, V9, P1633
[6]   Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Robanus-Maandag, EC ;
Bosch, CAJ ;
Duval, C ;
Pilotti, S ;
van de Vijver, MJ .
BRITISH JOURNAL OF CANCER, 2001, 84 (04) :539-544
[7]   Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-Year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group [J].
Bijker, Nina ;
Meijnen, Philip ;
Peterse, Johannes L. ;
Bogaerts, Jan ;
Van Hoorebeeck, Irene ;
Julien, Jean-Pierre ;
Gennaro, Massimiliano ;
Rouanet, Philippe ;
Avril, Antoine ;
Fentiman, Ian S. ;
Bartelink, Harry ;
Rutgers, Emiel J. Th. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3381-3387
[8]   Transformation of human and murine fibroblasts without viral oncoproteins [J].
Boehm, JS ;
Hession, MT ;
Bulmer, SE ;
Hahn, WC .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (15) :6464-6474
[9]   COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ [J].
Boland, GP ;
Butt, IS ;
Prasad, R ;
Knox, WF ;
Bundred, NJ .
BRITISH JOURNAL OF CANCER, 2004, 90 (02) :423-429
[10]   Oncogene-induced senescence as an initial barrier in lymphoma development [J].
Braig, M ;
Lee, S ;
Loddenkemper, C ;
Rudolph, C ;
Peters, AHFM ;
Schlegelberger, B ;
Stein, H ;
Dörken, B ;
Jenuwein, T ;
Schmitt, CA .
NATURE, 2005, 436 (7051) :660-665